ACHV Insider Trading
Insider Ownership Percentage: 2.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Achieve Life Sciences Insider Trading History Chart
This chart shows the insider buying and selling history at Achieve Life Sciences by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Achieve Life Sciences Share Price & Price History
Current Price: $2.65
Price Change: +0.30 (1.20%)
As of 03/13/2025 05:00 PM ET
Achieve Life Sciences Insider Trading History
Achieve Life Sciences Institutional Trading History
Data available starting January 2016
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Read More on Achieve Life Sciences
Volume
218,892 shs
Average Volume
256,400 shs
Market Capitalization
$91.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.67
Who are the company insiders with the largest holdings of Achieve Life Sciences?
Who are the major institutional investors of Achieve Life Sciences?
Which institutional investors are selling Achieve Life Sciences stock?
Within the last quarter, ACHV stock was sold by these institutional investors:
- Shay Capital LLC
- Alyeska Investment Group L.P.
- Franklin Resources Inc.
- Citadel Advisors LLC
Which institutional investors are buying Achieve Life Sciences stock?
During the last quarter, ACHV stock was bought by institutional investors including:
- Raymond James Financial Inc.
- Raymond James Financial Inc.
- Dumac Inc.
- JPMorgan Chase & Co.
- Northern Trust Corp
- Renaissance Technologies LLC
- Squarepoint Ops LLC
- Intech Investment Management LLC